CN111205233A - Preparation method of erlotinib - Google Patents
Preparation method of erlotinib Download PDFInfo
- Publication number
- CN111205233A CN111205233A CN202010021307.5A CN202010021307A CN111205233A CN 111205233 A CN111205233 A CN 111205233A CN 202010021307 A CN202010021307 A CN 202010021307A CN 111205233 A CN111205233 A CN 111205233A
- Authority
- CN
- China
- Prior art keywords
- formula
- reaction
- compound shown
- compound represented
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of erlotinib, which comprises the following steps: subjecting a compound represented by formula 1 to a cyclization reaction to obtain a compound represented by formula 2, subjecting a compound represented by formula 2 to a chlorination reaction to obtain a compound represented by formula 3, and subjecting a compound represented by formula 3 to a substitution salt-forming reaction to obtain erlotinib represented by formula 4. The preparation method of erlotinib hydrochloride can greatly shorten the production period, can effectively avoid the defects of long production period, serious environmental pollution, unstable intermediate, difficult purification of the product, complex operation and the like, and has the advantages of short reaction step, simple operation, easy reaction, high product purity, higher yield and lower cost. The addition amount of the reactants is controlled properly, the environmental requirement is clear, and a clear and new production direction is provided for the process production.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a preparation method of erlotinib.
Background
Erlotinib hydrochloride was originally developed by Astellas, Switzerland Hoffmann-LaRoche, and its CAS number is 183319-69-9 and its molecular formula is C22H23N3O4The erlotinib hydrochloride is a lung cancer targeted therapeutic drug, belongs to the epidermal growth factor receptor tyrosine kinase inhibitionThe erlotinib has a certain treatment effect on advanced NSCLE failed in chemotherapy, is superior to chemotherapy in the aspects of improving the survival quality and tolerance of patients, is approved in China in 2006 and 4 months, and is used for treating locally advanced or metastatic non-small cell lung cancer failed in at least one chemotherapy scheme.
Currently, most of erlotinib hydrochloride is prepared by nitration, cyclization treatment and other methods in China, the production period is as long as 16 hours, the production process is more, the operation is complex, the pollution of byproducts is serious, the industrial production efficiency and the cost are seriously influenced, and if the production period can be shortened, the erlotinib hydrochloride has better market prospect once the simulation is successful, so that the erlotinib preparation method is designed to solve the problems in the prior art.
Disclosure of Invention
The invention aims to provide a preparation method of erlotinib, which is a process route with short period, easy synthesis and environmental protection, and aims to solve the problems in the background art.
In order to achieve the purpose, the invention provides the following technical scheme: a preparation method of erlotinib, which comprises the following steps,
(1) subjecting methyl benzoate as a compound shown in formula 1 and ammonium formate to cyclization reaction in a formamide-protected environment so as to obtain quinazolinone as a compound shown in formula 2;
(2) chlorinating the quinazolinone compound shown as the formula 2 by thionyl chloride to obtain quinazoline compound shown as the formula 3;
(3) and (3) carrying out substitution salt-forming reaction on the quinazoline compound shown as the formula 3 so as to obtain erlotinib hydrochloride shown as the formula 4.
In one embodiment of the invention, the compound represented by formula 1, methyl benzoate and ammonium formate, in a molar ratio of 1:1, are mixed in a formamide-protected environment at a temperature of 160-165 ℃ for 3-3.5 hours to generate cyclization reaction.
In one embodiment of the present invention, methyl benzoate and ammonium formate in reaction formula 1 are reacted, the solvent is mixed with ethanol and benzene, and other reaction environment is not changed
In one embodiment of the present invention, the reaction molar ratio of methyl benzoate and ammonium formate in reaction formula 1 is 1: 0.5-5, and other reaction environments are not changed.
In one embodiment of the invention, methyl benzoate and ammonium formate are reacted in reaction scheme 1, the solvent for formamide is added in a ratio of 1: 1-10, and the other reaction environment is unchanged.
In one embodiment of the present invention, the reaction of methyl benzoate and ammonium formate in equation 1 is carried out at a temperature of 150 ℃ and 200 ℃ without changing other reaction environments.
In one embodiment of the present invention, methyl benzoate and ammonium formate in reaction formula 1 are reacted for 1 to 5 hours without changing other reaction environments.
In one embodiment of the invention, quinazolinone chlorination in reaction formula 2 is carried out with DMF as catalyst at a molar ratio of 1:1 and 80 ℃ for 40 minutes.
In one embodiment of the present invention, quinazolinone chlorination in reaction formula 2 is allowed to react, and the amount of DMF as a catalyst is changed, while the other reaction environment is unchanged.
In one embodiment of the invention, quinazolinone chlorination in reaction formula 2 is carried out in a molar ratio of 1: 0.5-5, and other reaction environments are not changed.
In one embodiment of the invention, quinazolinone chlorination in reaction formula 2 is carried out in a molar ratio of 1: 0.5-5, and other reaction environments are not changed.
In one embodiment of the present invention, quinazolinone chlorination in reaction formula 2 is allowed to react for 30-90 minutes, and other reaction environments are not changed.
In one embodiment of the present invention, the substitution salt formation in reaction formula 3 is carried out in the presence of DMF in a molar ratio of 1:1 at 80 ℃ for 1 hour.
In one embodiment of the present invention, the substitution salt formation in reaction formula 3 is performed with isopropanol as a reaction solvent, and the other reaction environment is unchanged.
In one embodiment of the invention, the substitution salt formation reaction in the reaction formula 3 is carried out, the reaction molar ratio is 1: 0.5-5, and other reaction environments are not changed.
In one embodiment of the invention, the substitution salt forming reaction in the reaction formula 3 is carried out at the reaction temperature of 60-120 ℃, and other reaction environments are not changed.
In one embodiment of the present invention, the substitution salt formation in reaction formula 3 is performed for 30 to 90 minutes, and the other reaction environment is not changed.
The following is a table of data for an embodiment of the invention:
compared with the prior art, the invention has the beneficial effects that: the preparation method of erlotinib hydrochloride can greatly shorten the production period and effectively avoid the defects of long production period, serious environmental pollution, unstable intermediate, difficult purification of the product, complex operation and the like;
the method has the advantages of short reaction steps, simple operation, easy reaction, high product purity, higher yield and lower cost. The addition amount of reactants is controlled properly, the environmental requirement is clear, and a clear and new production direction is provided for the process production;
the present invention will be described with reference to examples and embodiments, and various alterations and combinations made by those skilled in the art and conventional means are included in the scope of the present invention.
Drawings
FIG. 1 is an HPLC chromatogram of erlotinib of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1, an embodiment of the present invention:
the first embodiment is as follows:
adding (100g) methyl benzoate, 304mL formamide and 25.07g ammonium formate into a 1000mL reaction bottle, reacting at an internal temperature of 160-165 ℃ for 3-3.5 hours under stirring, stopping heating, cooling, and crystallizing at 0-10 ℃ for 3 hours under stirring. Filtering to obtain crude quinazolinone wet crystal, and vacuum drying at 50 deg.C overnight to obtain quinazolinone 79.7 g.
Example two:
adding 100g of mixed solution of methyl benzoate, 304mL of formamide and 200mL of ethanol and benzene into a 1000mL reaction bottle, adding 25g of ammonium formate, heating to 160-165 ℃ under the protection of nitrogen, heating under reflux for 10 hours, stopping heating, cooling, adding 300mL of saturated saline, extracting the reaction solution for 3 times by using 200mL of chloroform, combining organic phases, and distilling to remove the solvent to obtain 63.1g of quinazolinone.
Example three:
50g of quinazolinone fine product, 125mL of thionyl chloride and 5mL of DMMF were added into a 250mL single-neck flask, heated and refluxed at 85 ℃ at an external temperature, and stirred to be clear, and the time is taken for 40 min. Adding 208g of anhydrous sodium sulfate, drying for 2h, filtering, concentrating the filtrate under reduced pressure at 40 ℃ in a water bath until the filtrate is dry, adding 203mL of methyl tert-butyl ether and 212mL of ethyl acetate, heating and refluxing in a water bath at 80 ℃ until the filtrate is clear, continuing stirring for 15min, cooling to 25-30 ℃ for crystallization for 2h, filtering to obtain wet crystals of the SE-M crude product, and drying in vacuum at 40-50 ℃ for 4h to obtain 38.5g of the crude product.
Example four:
50g of quinazolinone fine product, 125mL of thionyl chloride and 10mL of DMMF were added into a 250mL single-neck flask, heated and refluxed at 85 ℃ at an external temperature, and stirred to be clear, and the time is taken for 40 min. Adding 208g of anhydrous sodium sulfate, drying for 2h, filtering, concentrating the filtrate under reduced pressure at 40 ℃ in a water bath until the filtrate is dry, adding 203mL of methyl tert-butyl ether and 212mL of ethyl acetate, heating and refluxing in a water bath at 80 ℃ until the filtrate is clear, continuing stirring for 15min, cooling to 25-30 ℃ for crystallization for 2h, filtering to obtain wet crystals of the SE-M crude product, and drying in vacuum at 40-50 ℃ for 4h to obtain 23g of the crude product.
The following five steps are carried out:
adding 150mLDMF and 15gSE-M fine product into a 250mL single-neck flask, heating, stirring and dissolving, adding 6g of 3-acetylene aniline, heating and stirring at an internal temperature of 80 ℃, continuing stirring for 1h after solid is separated out, cooling to 25-30 ℃, continuing stirring for 0.5h, filtering, leaching the wet crystal of the crude product by ethyl acetate, and performing vacuum drying for 4h at 40-50 ℃ to obtain 20g of erlotinib hydrochloride crude product.
Example six:
adding 15gSE-M fine product and isopropanol solution into a 250mL single-neck flask, heating, stirring and dissolving, adding 6g of 3-acetylene aniline, heating and stirring at an internal temperature of 80 ℃, refluxing the system for 4h, cooling to room temperature, generating precipitate, filtering, leaching crude wet crystals with ethyl acetate, drying in vacuum at 40-50 ℃ for 4h, and recrystallizing to obtain 17g of crude erlotinib hydrochloride.
The results of the invention show that the production period can be shortened by adopting methyl benzoate to carry out the reaction, the production efficiency is improved to a greater extent, the cost is saved, the reaction is easy to operate, and the invention is a production process which is suitable for the current industrial production, easy to react, low in cost and high in yield.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes in the embodiments and/or modifications of the invention can be made, and equivalents and modifications of some features of the invention can be made without departing from the spirit and scope of the invention.
Claims (16)
1. A preparation method of erlotinib, which is characterized by comprising the following steps:
(1) subjecting the compound represented by formula 1 to a cyclization reaction to obtain a compound represented by formula 2;
(2) subjecting the compound represented by the formula 2 to a chlorination reaction to obtain a compound represented by the formula 3;
(3) and (3) carrying out substitution salt-forming reaction on the compound shown in the formula 3 so as to obtain erlotinib shown in the formula 4.
2. The method for preparing erlotinib according to claim 1, wherein: the cyclization reaction is performed by contacting the compound represented by formula 1 with ammonium formate.
3. The method for preparing erlotinib according to claim 1, wherein: the cyclization reaction is carried out by contacting the compound represented by formula 1 with ammonium formate in a mixed solution of ethanol and benzene.
4. The method for preparing erlotinib according to claim 1, wherein: the contacting of the compound represented by the formula 1 with ammonium formate is carried out in the presence of formamide and no water.
Optionally, the molar ratio of the compound represented by formula 1 to the ammonium formate is 1:0.5-1: 5;
preferably, the molar ratio is 1: 1.
5. The method for preparing erlotinib according to claim 1, wherein: the compound shown in the formula 1 is contacted with ammonium formate at the temperature of 150-200 ℃;
optionally, the temperature is 150-200 ℃, preferably, the temperature is 160-165 ℃;
preferably, the temperature is 160 ℃.
6. The method for preparing erlotinib according to claim 1, wherein: the contact reaction time of the compound shown as the formula 1 and ammonium formate is 1-5 hours;
optionally, the time is 1 to 5 hours, preferably, the time is 3 to 3.5 hours.
7. The method for preparing erlotinib according to claim 1, wherein: the cyclization reaction is carried out in the presence of formamide and absolute ethanol.
8. The method for preparing erlotinib according to claim 1, wherein: in the chlorination reaction, the compound shown in the formula 2 reacts with thionyl chloride in the environment with DMF as a solvent;
optionally, in the chlorination reaction, the amount of DMF as a solvent is 1-15 ml;
preferably, the amount of DMF solvent is 5 ml.
9. The method for preparing erlotinib according to claim 1, wherein: in the chlorination reaction, the molar ratio of the compound shown in the formula 2 to thionyl chloride is 1:0.5-1: 5;
optionally, in the chlorination reaction, the molar ratio of the compound shown in the formula 2 to thionyl chloride is 1: 1.
10. The method for preparing erlotinib according to claim 1, wherein: in the chlorination reaction, the reaction temperature of the compound shown in the formula 2 and thionyl chloride is controlled;
optionally, the chlorination reaction is at a temperature of 60-120 ℃;
preferably, the temperature is 80-90 ℃.
11. The method for preparing erlotinib according to claim 1, wherein: in the chlorination reaction, the compound shown in the formula 2 and thionyl chloride react for 30-90 minutes;
optionally, the chlorination reaction time is 30-90 minutes;
preferably, the time is 40 to 50 minutes.
12. The method for preparing erlotinib according to claim 1, wherein: in the substitution salt-forming reaction, the compound shown in the formula 3 reacts with 3-acetylene aniline in a DMF (dimethyl formamide) solvent environment.
13. The method for preparing erlotinib according to claim 1, wherein: in the substitution salt-forming reaction, the compound shown in the formula 3 reacts with 3-acetylene aniline in an isopropanol solvent environment.
14. The method for preparing erlotinib according to claim 1, wherein: in the substitution salification reaction, the molar ratio of the compound shown in the formula 3 to 3-acetylene aniline is 1:0.5-1: 5;
optionally, in the substitution salt formation reaction, the molar ratio of the compound shown in the formula 3 to the 3-acetylene aniline is 1: 1.
15. The method for preparing erlotinib according to claim 1, wherein: in the substitution salt-forming reaction, the temperature of the reaction of the compound shown in the formula 3 and 3-acetylene aniline;
optionally, the substitution salt-forming reaction is at a temperature of 60-120 ℃;
preferably, the temperature is 80-90 ℃.
16. The method for preparing erlotinib according to claim 1, wherein: in the substitution salt-forming reaction, the compound shown in the formula 3 reacts with 3-acetylene aniline for 30-90 minutes;
optionally, the substitution salt formation reaction time is 30-90 minutes;
preferably, the time is 55 to 60 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010021307.5A CN111205233A (en) | 2020-01-09 | 2020-01-09 | Preparation method of erlotinib |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010021307.5A CN111205233A (en) | 2020-01-09 | 2020-01-09 | Preparation method of erlotinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111205233A true CN111205233A (en) | 2020-05-29 |
Family
ID=70783413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010021307.5A Pending CN111205233A (en) | 2020-01-09 | 2020-01-09 | Preparation method of erlotinib |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111205233A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102321033A (en) * | 2011-08-22 | 2012-01-18 | 江苏辉丰农化股份有限公司 | Preparation method of tarceva |
| WO2013156835A1 (en) * | 2012-04-16 | 2013-10-24 | Laurus Labs Private Limited | An improved process for the preparation of erlotinib hydrochloride form a |
| CN104725327A (en) * | 2015-03-03 | 2015-06-24 | 山东大学 | Environment-friendly method for preparing high-yield erlotinib hydrochloride |
-
2020
- 2020-01-09 CN CN202010021307.5A patent/CN111205233A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102321033A (en) * | 2011-08-22 | 2012-01-18 | 江苏辉丰农化股份有限公司 | Preparation method of tarceva |
| WO2013156835A1 (en) * | 2012-04-16 | 2013-10-24 | Laurus Labs Private Limited | An improved process for the preparation of erlotinib hydrochloride form a |
| CN104725327A (en) * | 2015-03-03 | 2015-06-24 | 山东大学 | Environment-friendly method for preparing high-yield erlotinib hydrochloride |
Non-Patent Citations (1)
| Title |
|---|
| 李铭东 等: "盐酸埃洛替尼的合成", 《中国医药工业杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109134435B (en) | Synthesis method of AZD9291 | |
| CN112079848A (en) | Synthesis method of baroxavir key intermediate | |
| CN112645869B (en) | Preparation method of chlorpheniramine maleate intermediate | |
| RU2074854C1 (en) | Method of synthesis of derivatives of o-(2-hydroxy-3-piperidino-1-propyl)-nicotinic acid amideoxime and their salts (variants), o-(2-hydroxy-3-piperidino-1-propyl)-nicotinic acid amideoxime pure crystalline base | |
| CN111205233A (en) | Preparation method of erlotinib | |
| CN112979544B (en) | Preparation method of cabozitinib or salt thereof | |
| CN113416150A (en) | Novel synthesis method of lobaplatin intermediate | |
| CN118436116A (en) | Nicotine and its derivative and preparation method | |
| CN114773176B (en) | Chlorpheniramine maleate impurity and preparation method and application thereof | |
| KR20140042805A (en) | Intermediate for synthesizing caspofungin and preparation method therefor | |
| CN112679570B (en) | Synthesis and purification method of tildipirosin | |
| CN114507180B (en) | Methyl-substituted azaheterocyclic compound C (sp 3 ) Method for self dehydroalkenylation of H bonds | |
| CN106008392B (en) | A kind of preparation method of the intermediate of cancer therapy drug Dasatinib | |
| CN111925317B (en) | Ropivacaine hydrochloride impurity and preparation method thereof | |
| CN111747926A (en) | Improved method for synthesis process of free hydroxypiperone alkali | |
| CN107011347A (en) | A kind of synthetic method of 4 chlorine 7H pyrrolo-es [2,3 d] pyrimidines | |
| CN111892544A (en) | 3- (aminomethyl) -4- (4-fluorophenyl) piperazine-1-carboxylic acid tert-butyl ester and synthesis method thereof | |
| CN112300059B (en) | Preparation method of PF-06651600 intermediate | |
| CN117069663B (en) | Synthesis method of rebaudinib intermediate V and synthesis method of rebaudinib | |
| CN114195684B (en) | Synthesis method of amino protecting group N-substituted chiral amino acid | |
| TWI845992B (en) | A method for preparing a hepatitis B virus nucleocapsid inhibitor | |
| CN111333528B (en) | Synthesis method of multi-configuration O-phenyl-serine compound | |
| CN117447351A (en) | Preparation method of lidocaine | |
| CN115232105A (en) | Teninil small molecule compound and preparation method thereof | |
| CN118812501A (en) | Preparation method of lipoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |